Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dyne Therapeutics Inc. Common Stock (DYN) vs SkyWest Inc (SKYW) Price & Performance

Dyne Therapeutics Inc. Common StockTrade
SkyWest IncTrade

Price performance (Past 24H)

Key statistics

Dyne Therapeutics Inc. Common Stock vs SkyWest Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while SkyWest Inc trades at $90.69 (market cap $3.67B). The key difference: SkyWest Inc is the larger of the two by market cap, and SkyWest Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and SkyWest Inc for 8 Days on average.

DYNSKYW
Market Cap
$2.86B$3.67B
Volume
3,341,579188,631
Sector
HealthIndustrials
52-Week High
$26.78$115.94
52-Week Low
$14.60$78.40
Typical Hold Time
0 Days8 Days
Enterprise Value
$2.18B$5.45B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dyne Therapeutics Inc. Common Stock

Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.

The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.

SkyWest Inc

SkyWest (SKYW) trades at $94.52, down 0.53% with a bearish technical signal despite positive analyst sentiment. The stock shows mixed earnings performance with a recent Q1 2026 beat but Q2 2026 miss, while maintaining solid fundamentals including a 9.78% net income margin and attractive valuation at 9.39 P/E. Recent news highlights fleet modernization efforts and expanding flying agreements as growth catalysts amid cost pressures.

The stock presents a compelling value opportunity with 58.8% analyst buy ratings and $112 consensus target, offering 18.5% upside potential. However, technical weakness and executive stock sales create near-term headwinds. Long-term prospects remain positive driven by operational improvements and strategic partnerships, though investors should monitor cost management and competitive pressures.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DYN
100% Buy0% Sell
Avg holding period · 0 Days
SKYW

No sentiment data available yet.

About Dyne Therapeutics Inc. Common Stock

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.

Read more on DYN →

About SkyWest Inc

SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.

Read more on SKYW →